Virus therapy takes on Platinum-Resistant ovarian cancer
NCT ID NCT05271318
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a chemotherapy called pegylated liposomal doxorubicin. The study enrolls 29 women and primarily aims to check the safety of this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TILT-123 (a modified virus that kills cancer cells and boosts the immune system), pembrolizumab (an immunotherapy drug), and pegylated liposomal doxorubicin (a chemotherapy drug)
What this could lead to
If this works, it could point toward a new treatment option for ovarian cancer that no longer responds to standard platinum chemotherapy.
What could go wrong
This is a very early, small trial (29 people) focused on safety, not effectiveness. The virus and drug combination may cause serious side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Docrates Cancer Center
Helsinki, 00180, Finland
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Northwell Heatlh/Lenox Hill Hospital
New York, New York, 10075, United States